52-78-8 Usage
Chemical Properties
mp 130-136oC
Originator
Nilevar,Searle,US,1956
Uses
Different sources of media describe the Uses of 52-78-8 differently. You can refer to the following data:
1. Norethandrolone is antinauseant and antiemetic highly specific and selective serotonin subtype 3 (5-HT3) receptor antagonist
2. Controlled substance (anabolic steroid). Androgen.
Manufacturing Process
Through a mixture of 11 parts of charcoal containing 5% palladium and 2,000 parts of dioxane a stream of hydrogen is passed for 60 minutes. Then 86 parts of 17-ethynyl-19-nortestosterone (Norethindrone) in 1,500 parts of dioxane are added and the mixture is hydrogenated until 2 mols of hydrogen are absorbed. The catalyst is then removed by filtration and the solvent is
evaporated under vacuum. The crystalline residue is dissolved in 2,700 parts of benzene and thus applied to a chromatography column containing 5,000 parts of silica gel. The column is washed with 2,700 parts of benzene, 4,500 parts of a 10% solution of ethyl acetate in benzene and 27,000 parts of a 20% solution of ethyl acetate in benzene and is then eluted with 30,000 parts of a 30% solution of ethyl acetate in benzene. The resulting eluate is concentrated under vacuum and the residue is recrystallized from methanol and dried to constant weight at 75°C. The 17-ethyl-19-nortestosterone thus obtained melts at about 140°C to 141°C.
Therapeutic Function
Androgen
Check Digit Verification of cas no
The CAS Registry Mumber 52-78-8 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 2 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 52-78:
(4*5)+(3*2)+(2*7)+(1*8)=48
48 % 10 = 8
So 52-78-8 is a valid CAS Registry Number.
InChI:InChI=1/C20H30O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h12,15-18,22H,3-11H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1
52-78-8Relevant articles and documents
COMPOUNDS FOR TARGETED THERAPIES OF CASTRATION RESISTANT PROSTATE CANCER
-
Paragraph 00199; 00200, (2020/09/12)
The present invention generally relates to new compounds for therapeutic uses. In particular, this disclosure relates to novel tetracyclic compounds useful for treatment of cancer, especially castration resistant prostate cancer. Pharmaceutical composition matters and methods for treating a cancer patient by administering therapeutically effective amounts of such compound alone or together with other therapeutics are within the scope of this disclosure.
Synthesis of 13-alkyl-gon-4-ones
-
, (2008/06/13)
The preparation of 13-methylgon-4-enes and novel 13-polycarbonalkylgon-4-enes by a new total synthesis is described. 13-Alkylgon-4-enes having progestational, anabolic and androgenic activities are prepared by forming a tetracylic gonane structure unsaturated in the 1,3,5(10),9(11) and 14-positions, selectively reducing in the B- and C-rings, and converting the aromatic A-ring compounds so-produced to gon-4-enes by Birch reduction and hydrolysis.
